CD274 and cervical cancer: This evidence suggests that dysregulated PD-1/PD-L1-mediated immunity may contribute to HPV-associated cervical oncogenesis, making anti-PD-1/PD-L1 immunotherapies particularly promising for HPV+ cervical cancer patients.